About Bristol-myers squibb farmaceutica
Bristol-Myers Squibb Farmaceutica: Delivering Innovative Medicines to Patients with Serious Diseases
Bristol-Myers Squibb Farmaceutica is a leading global biopharmaceutical company that is committed to discovering, developing, and delivering innovative medicines to patients with serious diseases. With a rich history spanning over 150 years, Bristol-Myers Squibb has been at the forefront of medical research and development, bringing life-saving treatments to millions of people around the world.
At Bristol-Myers Squibb Farmaceutica, our mission is simple: we strive to improve the lives of patients by developing breakthrough therapies that address unmet medical needs. We are dedicated to advancing science and medicine through cutting-edge research and development programs that focus on oncology, immunology, cardiovascular disease, fibrosis and other serious illnesses.
Our commitment to innovation is reflected in our pipeline of promising new drugs that are designed to target specific disease pathways. Our scientists work tirelessly in state-of-the-art laboratories around the world to discover new compounds and develop novel treatment approaches that can help patients live longer and healthier lives.
One area where Bristol-Myers Squibb has made significant progress is in the field of oncology. We have developed several groundbreaking cancer treatments that have transformed the way cancer is treated today. Our immuno-oncology portfolio includes Opdivo (nivolumab), which was approved by the FDA for advanced melanoma in 2014 and has since been approved for multiple indications across several tumor types; Yervoy (ipilimumab), which was approved by the FDA for advanced melanoma in 2011; Empliciti (elotuzumab), which was approved by the FDA for multiple myeloma in combination with lenalidomide/dexamethasone; as well as other promising compounds currently under development.
In addition to our work in oncology, Bristol-Myers Squibb is also focused on developing treatments for other serious diseases. Our cardiovascular portfolio includes Eliquis (apixaban), which is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; and Orencia (abatacept), which is used to treat rheumatoid arthritis. We are also working on developing treatments for fibrosis, a group of diseases that affect the connective tissue in organs such as the lungs, liver, and kidneys.
At Bristol-Myers Squibb Farmaceutica, we are committed to making a positive impact on society by improving patient outcomes and advancing medical science. We believe that our success depends on our ability to attract and retain talented individuals who share our passion for innovation and excellence. That's why we invest heavily in employee development programs that help our people grow both personally and professionally.
In conclusion, Bristol-Myers Squibb Farmaceutica is a global leader in biopharmaceutical research and development with a strong commitment to delivering innovative medicines to patients with serious diseases. Our mission is clear: we strive to improve patient outcomes by discovering breakthrough therapies that address unmet medical needs. With a rich history of scientific discovery spanning over 150 years, we are well-positioned to continue making significant contributions to medical science for many years to come.